Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast)
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Sponsor: MedImmune LLC
Listed as NCT01862900, this PHASE1 trial focuses on Liver Metastases and Lung Metastases and remains completed. Sponsored by MedImmune LLC, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
- Providence Cancer Center, Earle A. Chiles Research Institute
- Providence Health & Services
- Robert W. Franz Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .